Medical Devices

A small Canadian firm is partnering with the nation's top research body to turn a unique Greenlandic mineral into a powerful new tool for CO2 removal.

Conexeu Sciences hits a key manufacturing milestone for its innovative wound-healing gel, but the path to FDA clearance and a crowded market remains a challenge.

A Canadian upstart is poised to unlock a massive, untreated market by moving glaucoma surgery from the OR to the office. This isn't just a new device; it's a strategic dismantling of a decades-old bottleneck.

K-beauty leader Rael disrupts the U.S. market with advanced hydrogel masks and the first Korean-made tampon, pioneering a new era of 'K-Wellness'.

Beta Bionics faces a shareholder investigation after a slowdown in patient growth spooked investors. We decode the numbers and the broader risks of growth metrics.

New trial data shows Sequel Med Tech's twiist™ AID system could bring much-needed simplicity and safety to millions with insulin-treated type 2 diabetes.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

Medtronic veteran Jesse Litwak joins ProVerum, a move signaling the BPH innovator is shifting from R&D to aggressive commercial scale-up with its new ProVee tech.

A CPG veteran launches Lioness, a functional gummy snack for women. Can timed ingredients and a massive retail launch redefine the wellness market?

A Chinese medical device company just won top honors from global investors. It's not just a trophy—it's a masterclass in corporate strategy and global ambition.

With its new SmartBioSurface slides, Italian firm Tethis aims to solve a major lab challenge. The key? A nanotech surface that could reshape disease research.

Insulet unveils new data for its Omnipod 6 and a fully closed-loop system, signaling a major strategic push into the vast, untapped type 2 diabetes market.

Portable oxygen offers freedom, but as companies market summer travel, a closer look reveals that not all devices may deliver on their life-sustaining promise.

A recall of Target's popular baby wipes over dangerous bacteria raises critical questions about private label safety, supplier oversight, and consumer trust.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

A new alliance between General Fluidics and Invetech seeks to move lab testing from centralized facilities to the clinic, promising faster, more accessible care.

Florida Southern College secures a rare 10-year nursing accreditation, signaling a critical boost for a state grappling with a persistent nursing shortage.

Allen Control Systems' massive funding for its autonomous Bullfrog weapon reveals a new reality: venture capital is now funding the future of warfare.